Glaukos Q3 sales rise 58% to $211.0 million; 2026 sales guidance raised
Glaukos reported third-quarter 2026 net sales of $211.0 million, up 58% from $133.5 million a year earlier, and GAAP net income of $2.0 million, or $0.03 per diluted share, compared with a net loss of $16.2 million in the prior-year quarter. The company raised its 2026 net sales guidance to $775 million to $785 million from $680 million to $700 million and gave preliminary 2027 net sales guidance of $1 billion.
Key points
- Q3 2026 net sales were $211.0 million, up 58% year over year; U.S. Glaucoma sales were $118.6 million and Corneal Health sales were $59.0 million.
- GAAP net income was $2.0 million, or $0.03 per diluted share; non-GAAP net income was $28.5 million, or $0.47 per diluted share.
- 2026 net sales guidance was raised to $775 million to $785 million from $680 million to $700 million.
- Cash, short-term investments and restricted cash were $339.8 million at September 30, 2026, up $50.5 million from June 30, 2026, with no debt.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.